About Moximed
Moximed is a company based in Hayward (United States) founded in 2006 by Josh Makower and Anton Clifford. Moximed has raised $262.34 million across 8 funding rounds from investors including Runway Growth Capital, Advent Life Sciences and GBS. Moximed offers products and services including MISHA Knee System. Moximed operates in a competitive market with competitors including Allay Therapeutics, Abanza Tecnomed, Sparta Biomedical, Jointmedica and CoreTissue BioEngineering, among others.
- Headquarter Hayward, United States
- Founders Josh Makower, Anton Clifford
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Moximed Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$262.34 M (USD)
in 8 rounds
-
Latest Funding Round
$62.71 M (USD), Series D
Aug 07, 2024
-
Investors
Runway Growth Capital
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Moximed
Moximed offers a comprehensive portfolio of products and services, including MISHA Knee System.
Implantable shock absorber for relieving knee osteoarthritis pain and improving mobility.
People of Moximed
Unlock access to complete
Unlock access to complete
Funding Insights of Moximed
Moximed has successfully raised a total of $262.34M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $62.71 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Moximed
Moximed has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Runway Growth Capital, Advent Life Sciences and GBS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early and mid-stage life science focused VC firm investing in the US and Europe
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked |
Investor details for Moximed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Moximed
Investment portfolio details for Moximed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Moximed
Detailed financials for Moximed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Moximed Comparisons
Peer comparison for Moximed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Moximed
Moximed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Allay Therapeutics, Abanza Tecnomed, Sparta Biomedical, Jointmedica and CoreTissue BioEngineering, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Post-surgical pain drugs are developed using non-opioid biopolymer technology.
|
|
| Locked | Locked | Locked |
Surgical instruments for sports medicine procedures are developed.
|
|
| Locked | Locked | Locked |
Synthetic cartilage platforms are developed for orthopedic surgeons.
|
|
| Locked | Locked | Locked |
Smart knee replacement devices matching natural anatomy are provided.
|
|
| Locked | Locked | Locked |
Implantable medical devices are developed from decellularized living tissues.
|
Detailed competitors of Moximed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Moximed
Complete news archive for Moximed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Moximed
Moximed was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Moximed is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Christopher Gleason is the current CEO of Moximed.
Moximed is a funded company, having raised a total of $262.34M across 8 funding rounds to date.
Moximed was founded in 2006 and is headquartered in Hayward, United States. Medical devices for orthopedic applications are developed, with a focus on knee osteoarthritis treatments. The KineSpring Knee Implant System is provided as the primary product, functioning as a partial load absorber that reduces knee joint pressure by up to 13 kg for eligible patients prior to full joint replacement. Operations center on implant innovation in the medtech sector.
Moximed's top competitors include Allay Therapeutics, Sparta Biomedical and Abanza Tecnomed.
Moximed offers MISHA Knee System.
Moximed has 12 investors. Key investors include Runway Growth Capital, Advent Life Sciences, GBS, Gilde Healthcare, and Morgenthaler.